clinicaltrialsarena5h
Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial
Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study.
RSV vaccines are available for vulnerable adults and the ill. They just can’t afford them.
Vulnerable and elderly Australians are missing out on protection against respiratory syncytial virus (RSV) because many can’t ...
Here's How to Play Pfizer Stock Before Q4 Earnings Release
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the ...
cidrap.umn5d
Real-world study: RSV vaccine 78% to 80% effective against infection, severe illness in older US veterans
The estimated effectiveness of the respiratory syncytial virus (RSV) among older US veterans in the 2023-2024 respiratory ...
pulmonologyadvisor6d
FDA Alert: Pulmonology Drug Approvals, Recalls, and Device Updates
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.